ChemoCentryx, Inc.
850 Maude Avenue
Mountain View
California
94043
United States
Tel: 650-210-2900
Fax: 650-210-2910
Website: http://www.chemocentryx.com/
Email: info@chemocentryx.com
About ChemoCentryx, Inc.
"People Deserve Better Medicine and not just a longer life---a better life."
Located in the heart of the Silicon Valley, ChemoCentyx is a biotechnology company that focuses on chronic kidney diseases, immuno-oncology, and other autoimmune and inflammatory diseases.
Our vision can only be accomplished through talented people who share our culture and values.
We have created a corporate culture of scientific innovation, placing emphasis on hard work, honesty, and industry-leading technology in a fun, team-oriented atmosphere. We treat each other with respect at all times. We expect employees to add value as individuals and as team members. We work hard to nurture this environment.
As a late clinical development stage company, we are focused on a pipeline that discovers, develops and commercializes orally-administered therapeutics.
"ChemoCentryx: Great Science, Great Medicine"
197 articles with ChemoCentryx, Inc.
-
After the July 4 holiday, the U.S. FDA has several things on their immediate calendar, including a couple target action dates and an advisory committee hearing. Here’s a look.
-
ChemoCentryx Announces Filing of Amendment to NDA Submission and Extension of the PDUFA Review Period for Avacopan in the Treatment of ANCA-Associated Vasculitis
7/6/2021
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that, following consultations with the U.S. Food and Drug Administration (FDA), it filed an amendment to its New Drug Application (NDA) for avacopan for the treatment of Anti-neutrophil Cytoplasmic Autoantibody (ANCA)-associated vasculitis, addressing points raised during the FDA Advisory Committee meeting on May 6, 2021
-
ChemoCentryx to Participate in the Raymond James 2021 Human Health Innovations Conference
6/16/2021
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Raymond James 2021 Human Health Innovations Conference on Wednesday, June 23 at 10:40 a.m. ET.
-
ChemoCentryx Announces Abstract on Avacopan in ANCA-Associated Vasculitis Selected as One of the Ten Best Abstracts at the ERA-EDTA Congress
6/8/2021
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced presentations highlighting outcomes of the Company’s Phase III ADVOCATE trial and Phase II ACCOLADE and LUMINA-1 trials as part of the annual meeting of the ERA-EDTA (European Renal Association – European Dialysis and Transplant Association), held in Berlin, Germany and virtually June 5-8, 2021
-
The FDA released a briefing document that expressed concerns over ChemoCentryx’s avacopan. Company shares plummeted 46.5% at the news.
-
ChemoCentryx Announces Results of FDA Advisory Committee Meeting on Avacopan in ANCA-Associated Vasculitis
5/7/2021
ChemoCentryx, Inc., announced the outcome of the U.S. Food and Drug Administration Arthritis Advisory Committee on avacopan for the treatment of Antineutrophil Cytoplasmic Autoantibody -associated vasculitis.
-
The U.S. FDA cites concerns regarding clinical data for ChemoCentryx’s investigational rare autoimmune disease therapy avacopan. Shares in the company plunged 46.5% lower following the release of the document.
-
ChemoCentryx Reports First Quarter 2021 Financial Results and Recent Highlights
4/29/2021
Applications for regulatory approval of avacopan in ANCA-associated vasculitis under review in the United States, Europe and Japan; PDUFA goal date of July 7, 2021, with Advisory Committee scheduled for May 6
-
ChemoCentryx to Hold First Quarter 2021 Financial Results Conference Call on Thursday, April 29, 2021
4/22/2021
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's first quarter 2021 financial results will be released after market close on Thursday, April 29, 2021.
-
ChemoCentryx’s Oral PD-L1 inhibitor, CCX559, Featured in Poster Presentation at the 2021 American Association for Cancer Research (AACR) Annual Meeting
4/9/2021
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company’s orally-administered small molecule PD-L1 inhibitor, CCX559, will be featured in a poster presentation at the virtual 2021 Annual Meeting of the American Association for Cancer Research (AACR)
-
ChemoCentryx to Host Virtual R&D Day on April 14, 2021
4/7/2021
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that it will host a virtual R&D Day on Wednesday, April 14, 2021 beginning at 12:30 p.m. ET.
-
ChemoCentryx Announces Appointment of Susan M. Kanaya to Board of Directors
3/8/2021
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the appointment of Susan M. Kanaya, the Company’s Executive Vice President and Chief Financial and Administrative Officer, to the ChemoCentryx Board of Directors effective March 2, 2021.
-
ChemoCentryx Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights
3/1/2021
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced financial results for the fourth quarter and full year ended December 31, 2020 and provided an overview of recent corporate highlights.
-
ChemoCentryx to Present at Two Upcoming Investor Conferences - Feb 25, 2021
2/25/2021
ChemoCentryx, Inc., announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences:.
-
ChemoCentryx Appoints Tausif (‘Tosh’) Butt as Executive Vice President and Chief Operating Officer
2/24/2021
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the appointment of Tausif (‘Tosh’) Butt as Executive Vice President and Chief Operating Officer, reporting directly to President and Chief Executive Officer Thomas J. Schall, Ph.D. In this new capacity at ChemoCentryx,
-
ChemoCentryx to Hold Fourth Quarter and Full Year 2020 Financial Results Conference Call on Monday, March 1, 2021
2/23/2021
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's fourth quarter and full year 2020 financial results will be released after market close on Monday, March 1, 2021.
-
ChemoCentryx Announces Publication in The New England Journal of Medicine of Results of the Pivotal Phase III ADVOCATE Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis
2/17/2021
-- Treatment with avacopan in the absence of daily oral prednisone led to remission at week 26 and superiority in sustaining remission at 52 weeks compared to the prednisone group -- -- Avacopan’s effects on kidney function, patient Quality of Life, and reduction in overall glucocorticoid-related toxicities also described --
-
ChemoCentryx to Participate in Two Upcoming Investor Conferences
1/6/2021
ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences and participate in a panel discussion hosted by former FDA Commissioner, Scott Gottlieb, M.D.: 39th Annual J.P. Morgan Healthcare Conference Wednesday, January 13 at 11:40 a.m. Eastern Time H.C. Wainwright Virtual BioConnect Conference On-demand presentation a
-
VFMCRP and ChemoCentryx Provide Topline Results From ACCOLADE Trial of Avacopan in C3 Glomerulopathy Including Improved Estimated Glomerular Filtration Rate (eGFR)
12/21/2020
The change from baseline to week 26 in C3 glomerulopathy histologic index (C3G HI) for disease activity (primary endpoint) was not statistically different between the two treatment groups, while the C3G HI for disease chronicity
-
ChemoCentryx and VFMCRP Provide Topline Results from ACCOLADE Trial of Avacopan in C3 Glomerulopathy Including Improved Estimated Glomerular Filtration Rate (eGFR)
12/21/2020
As in ANCA vasculitis, avacopan demonstrated statistically significant improvement in renal function as measured by eGFR compared to placebo over 26 weeks of blinded treatment The change from baseline to Week 26 in C3 Glomerulopathy Histologic Index (C3G HI) for Disease Activity (primary endpoint) was not statistically different between the two treatment groups, while the C3G HI for Disease Chronicity